Catalogue preview · final packaging and presentation may vary if stockedFive choices across your ballotUse votes only for compounds you would consider ordering
One vote per compoundEach candidate can be selected once on this browser
Flexible interest signalRemove or reassign a vote whenever you like
MAZDUTIDE
Mazdutide is a single dual agonist engineered to activate GLP-1 and glucagon receptors. It combines an incretin pathway with a glucagon pathway, making it a useful comparison with GLP-1-only, GIP/GLP-1, and triple-agonist designs.
Loading your saved choices…
MAZDUTIDE is currently being evaluated through customer voting and is not available to order. Final product specifications and batch documentation will be published only if it joins the catalogue.
This page records catalogue interest only. If MAZDUTIDE is selected for supply, Puffin will publish the confirmed format, batch documentation, and laboratory preparation information on the product listing.
Storage and handling requirements depend on the final supplied format. Confirmed instructions will be provided with the batch details if this candidate is added to the catalogue.
Understanding Mazdutide
Explore the science, research focus, and key information behind this compound.
What is Mazdutide?+
Mazdutide is useful when the study pairs GLP-1 activity with a glucagon-receptor component rather than GIP.
What Researchers Study+
Researchers examine Dual-receptor activity, Incretin signalling, and Energy-regulation models.
How Mazdutide Works+
GLP-1 receptor activity contributes glucose-dependent and food-intake signalling, while glucagon-receptor activity affects hepatic and energy-metabolism pathways. The central research question is how the two activities are balanced in one molecule.
Research at a Glance+
A dual GLP-1/glucagon programme reached regulatory approval in China. Randomized phase 3 trials evaluated Innovent’s defined once-weekly mazdutide product in Chinese adults. The resulting evidence and approval do not establish equivalence for separately sourced research material. Read the peer-reviewed GLORY-1 trial. Approval is product- and country-specific. A molecule may be approved by one regulator and remain unapproved elsewhere. The page should state where approval exists and avoid turning regional status into a global claim. Mazdutide is dual—but not another tirzepatide. Mazdutide combines GLP-1 with glucagon; tirzepatide combines GIP with GLP-1. The shared GLP-1 component does not make their second pathways interchangeable.
If this candidate is added to the catalogue, it would be offered for controlled laboratory research only. It is not for human consumption and is not represented as a medicine, treatment, supplement, or substitute for an approved product.